Athersys, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Z. Kasey Rosado
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3201 Carnegie Avenue Cleveland OH United States of America 44115-2634
- IPO Date
- Jun 12, 2007
- CIK
- 0001368148
- Website
- athersys.com
- Similar Companies
- Business
- Athersys, Inc. (ATHX) is a clinical-stage biotechnology company focused on the research, development, and commercialization of regenerative medicine therapies, particularly its proprietary MultiStem allogeneic off-the-shelf stem cell platform. MultiStem targets neurological conditions such as ischemic stroke; inflammatory and immune disorders including acute respiratory distress syndrome; cardiovascular diseases; pulmonary conditions; and other critical care indications like trauma complications and hematopoietic stem cell transplant support, with clinical programs in Phase 3 for stroke in North America, Europe, and Japan. The company, founded in 1995 and headquartered in Cleveland, Ohio, with operations in Leuven, Belgium, serves patients and healthcare providers in the United States, Europe, Japan, and other regions through collaborations and licensing agreements. Recent major developments include filing for Chapter 11 bankruptcy protection in January 2024, followed by conversion to Chapter 7 liquidation in September 2024; execution of a memorandum of understanding with Healios K.K. in 2023 granting global rights to MultiStem for acute respiratory distress syndrome, accompanied by upfront payments and potential milestones; engagement of Outcome Capital in 2023 to evaluate strategic alternatives such as mergers, asset sales, or investments; and completion of warrant exercises and public offerings in 2023 to extend liquidity amid ongoing clinical and operational challenges.
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)
Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys Director Jane Wasman Appointed Board Chair
Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Why Is Athersys (ATHX) Stock Down 36% Today?
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Athersys to Host Business Update Conference Call on August 9th
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma
Athersys Restructures Debt with Supplier
Athersys Reports First Quarter 2023 Financial Results and Business Highlights